Rate My Professor Timothy Stout

J. Timothy Stout, MD, PhD, MBA, is Chair, Sid W. Richardson Professor, and Margarett Root Brown Chair in the Department of Ophthalmology at Baylor College of Medicine in Houston, Texas. He also directs the Cullen Eye Institute, positions he has held since 2013. Prior to Baylor College of Medicine, Dr. Stout served as Professor in the Departments of Ophthalmology and Molecular Genetics at Oregon Health & Science University in Portland, Oregon, and as Vice President for Commercialization Strategies there. He has directed the Clayton Gene Therapy Laboratories since 1995. Dr. Stout earned his MD and PhD in Molecular Genetics from Baylor College of Medicine, completed a Pediatrics internship at Baylor College of Medicine, an Ophthalmology residency and Surgical Retina fellowship at the University of Southern California-Doheny Eye Institute in Los Angeles, California, a Medical Retina fellowship at Moorfields Eye Hospital in London, England, and an MBA from the University of Oregon.

Dr. Stout's research specializations include human gene and cell-based therapy for proliferative and inherited ocular disease, retinal disease genotype-phenotype correlation, ocular disease gene mapping and discovery, pediatric vitreoretinal diseases and surgery, genetics, and stem cell therapy. He is certified by the American Board of Ophthalmology and is a member of the American Academy of Ophthalmology, American College of Surgeons, American Medical Association, American Ophthalmological Society, American Society of Human Genetics, American Society of Gene Therapy, Association for Research in Vision and Ophthalmology, Association of University Professors of Ophthalmology, International Society for Genetic Eye Diseases, Macula Society, Houston Ophthalmological Society, Texas Medical Association, and Texas Ophthalmological Association. Key publications include Moshiri A et al., 'A nonhuman primate model of inherited retinal disease,' J Clin Invest (2019); Fouladi N et al., 'Safety and Efficacy of OXB-202, a Genetically Engineered Tissue Therapy for the Prevention of Rejection in High-Risk Corneal Transplant Patients,' Hum Gene Ther (2018); Pennesi ME et al., 'Results at 5 Years After Gene Therapy for RPE65-Deficient Retinal Dystrophy,' Hum Gene Ther (2018); Weleber RG et al., 'Results at 2 years after Gene Therapy for RPE65-Deficient Leber Congenital Amaurosis and Severe Early-Childhood-Onset Retinal Dystrophy,' Ophthalmology (2016); and Stout JT, 'The Rocky Road to Successful Human Gene Therapy,' Transactions of the American Ophthalmological Society (2014).